Finerenone for Cardiorenal Protection in Diabetic CKD: Impact on Renal Function Decline and Heart Failure

College of Physicians and Surgeons Pakistan

Status: Not yet enrolling

Conditions: Diabetic Kidney Disease (DKD); Heart Failure

Treatments: Drug: Finerenone

Study type: Interventional

Funder types: Other

Identifiers

NCT07326631

22126

Details and patient eligibility

About

To assess the effect of Finerinone on slowing renal function decline and improving cardiovascular outcomes, particularly heart failure risk, in patients with diabetic CKD.

Enrollment: 120 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults aged ≥18 years.
• Diagnosed cases of type 2 diabetes mellitus.
• Chronic kidney disease with eGFR 25-90 mL/min/1.73m² and/or UACR ≥30 mg/g.
• On stable ACE inhibitor or ARB therapy for at least 4 weeks.
• Serum potassium ≤4.8 mmol/L.
• Provided written informed consent.

Exclusion criteria

• Symptomatic heart failure (NYHA class II-IV).
• eGFR <25 mL/min/1.73m² or on maintenance dialysis.
• Known non-diabetic kidney disease.
• Recent major cardiovascular event (within 30 days).
• Serum potassium >4.8 mmol/L or history of severe hyperkalaemia.
• Contraindication or hypersensitivity to finerenone.
• Pregnancy or lactation.
• Any condition limiting compliance or follow-up.

Trial design

Primary purpose: Prevention

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

120 participants in 1 patient group

Finerenone Group

Experimental group

Description:

Finerenone Drug

Treatment:

Drug: Finerenone